Aurdan Capital Management LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Aurdan Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 9,043 shares of the medical research company's stock, valued at approximately $4,704,000. Thermo Fisher Scientific comprises 1.8% of Aurdan Capital Management LLC's holdings, making the stock its 18th biggest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Perennial Advisors LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $8,085,000. Value Partners Investments Inc. increased its position in Thermo Fisher Scientific by 8.1% during the fourth quarter. Value Partners Investments Inc. now owns 5,196 shares of the medical research company's stock valued at $2,701,000 after acquiring an additional 389 shares during the last quarter. AlphaCore Capital LLC boosted its position in Thermo Fisher Scientific by 364.6% in the fourth quarter. AlphaCore Capital LLC now owns 1,626 shares of the medical research company's stock worth $846,000 after purchasing an additional 1,276 shares during the last quarter. Forum Financial Management LP grew its stake in shares of Thermo Fisher Scientific by 45.0% during the 4th quarter. Forum Financial Management LP now owns 3,192 shares of the medical research company's stock valued at $1,661,000 after purchasing an additional 991 shares during the period. Finally, Baer Investment Advisory LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $799,000. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,075 shares of company stock worth $7,305,942. Corporate insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on TMO shares. UBS Group decreased their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Citigroup cut their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $2.12 during midday trading on Friday, hitting $401.63. The company's stock had a trading volume of 812,453 shares, compared to its average volume of 1,875,306. The company has a market cap of $151.61 billion, a P/E ratio of 24.30, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 12-month low of $390.50 and a 12-month high of $627.88. The business's 50 day simple moving average is $433.07 and its 200 day simple moving average is $501.01.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the company earned $5.11 EPS. The company's quarterly revenue was up .2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.